中国药物评价2016，Vol.33Issue(4)：239-245,7.
达利珠单抗诱导预防肾移植后急性免疫排斥反应的Meta分析
Effects of Daclizumab Used in Treatment for the Acute Rejection after Renal Transplant:A Meta-analysis
摘要
Abstract
Objective:To systematically evaluate the efficacy and safety of daclizumab on post-renal-transplant patients.Methods:Chinese databases including VIP,WANFANG and CNKI were searched by words‘daclizumab’ and‘renal transplant’ and ‘acute rejec-tion’ or‘Zenapax’ in both Chinese and English for relevant literatures published from Jan 1,2001 to July 13,2016.After unqualified arti-cles being eliminated, quality assessment, data extraction and Meta-analysis using RevMan 5.2 software were implemented.Results:Af-ter eliminating and retrieving,63 studies were preliminary selected and 8 of them were finally involved.Meta-analysis results show that the effective rates of treatments between experimental group and control group were statistically different[OR=0.41,95%CI(0.29,0.59),P<0.00001],while the adverse reaction rates(opportunistic infection)have no statistically significant difference [OR=1.01,95%CI (0.68,1.52)].Conclusion:Treatments of 1-dose or 2-dose daclizumab combined with conditional triple immune-suppressive therapy can efficiently reduce the rate of acute rejection and has no significant effects on opportunistic infection rates on post-renal-transplant pa-tients for 6 months.关键词
达利珠单抗/肾移植/Meta分析Key words
Daclizumab/Renal transplant/Meta-analysis分类
医药卫生引用本文复制引用
陈致远,邵蓉..达利珠单抗诱导预防肾移植后急性免疫排斥反应的Meta分析[J].中国药物评价,2016,33(4):239-245,7.
